Article Versions Notes

Darré H, Masson P, Nativel A, Villain L, Lefaudeux D, Couty C, Martin B, Jacob E, Duruisseaux M, Palgen J-L, et al. Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma. Biomedicines. 2024; 12(3):704. https://doi.org/10.3390/biomedicines12030704

Darré, Hippolyte, Perrine Masson, Arnaud Nativel, Laura Villain, Diane Lefaudeux, Claire Couty, Bastien Martin, Evgueni Jacob, Michaël Duruisseaux, Jean-Louis Palgen, and et al. 2024. "Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma" Biomedicines 12, no. 3: 704. https://doi.org/10.3390/biomedicines12030704

Darré, H., Masson, P., Nativel, A., Villain, L., Lefaudeux, D., Couty, C., Martin, B., Jacob, E., Duruisseaux, M., Palgen, J.-L., Monteiro, C., & L’Hostis, A. (2024). Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma. Biomedicines, 12(3), 704. https://doi.org/10.3390/biomedicines12030704